Influence of gut microbiome on Tamoxifen metabolism

Influence of gut microbiome on Tamoxifen metabolism - TAMENDOX-Micorbiome

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00029694

Enrollment

100

Registered

2022-07-22

Start date

2022-08-24

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C50

Interventions

Group 1: Selected patients on continuing tamoxifen therapy (20 mg per day) who have already participated in the TAMENDOX study (EudraCT no.: 2016-000418-31). A plasma and a stool sample will be obtain

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Present, signed "Informed Consent Form for the Establishment of a Biomaterial Bank in the TAMENDOX Study". - continuing tamoxifen therapy (20 mg per day) - completed 18th year of age - ability to give consent

Exclusion criteria

Exclusion criteria: - lack of informed consent

Design outcomes

Primary

Measure	Time frame
- Plasma concentration of tamoxifen and metabolites - Concentration of tamoxifen and metabolites in stool sample - Composition of the bacterial population in the stool sample	—

Countries

Germany

Contacts

Public ContactMatthias Schwab

Dr. Margarete Fischer-Bosch - Institut für Klinische Pharmakologie

matthias.schwab@ikp-stuttgart.de+49 (0)711 / 8101-3700

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026